US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Latest News about Can/Fite

Recent news which mentions Can/Fite

Industry Analysts Seemingly Sing Praises For This Stock After Phase III Trial Results
Tickers CANF JNJ MRK PFE
Tags Biotech Market News Can/Fite
From Benzinga
CANF: Beginning to Flex Its Muscles; Initiating With OUTPERFORM Rating, $6.00 Price Target
Tickers CANF
Tags Biotech Market News Can/Fite
From Benzinga
Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug
Tickers AMGN CANF CELG PFE
Tags CELG Benzinga Partner Content
From Benzinga
Race to Effective Psoriasis Treatment: Can-Fite's Piclidenoson May Edge Over High-Flying Amgen's Otezla. Here's Why
Tags Can/Fite Biotech Market News
From Benzinga